GLAUKOS Corp
Glaukos Corporation (NYSE: GKOS) is an ophthalmic pharmaceutical and medical technology company developing and commercializing therapies for glaucoma, corneal disorders, and retinal disease. Its products include micro-invasive glaucoma surgery devices, sustained-release drug-delivery implants, and bio-activated… From the company’s description.
In fiscal 2025, GLAUKOS Corp reported revenue of $507.44M, up 32.3% from fiscal 2024, and a net loss of $187.69M. Its operating margin was −39.3%, and operations used $14.79M in cash. Over the twelve months to Jun 30, 2026, revenue was $612.84M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What GLAUKOS Corp does
In the company’s own words
Glaukos Corporation (NYSE: GKOS) is an ophthalmic pharmaceutical and medical technology company developing and commercializing therapies for glaucoma, corneal disorders, and retinal disease. Its products include micro-invasive glaucoma surgery devices, sustained-release drug-delivery implants, and bio-activated pharmaceutical therapies. The iStent family of micro-bypass devices treats glaucoma by restoring aqueous humor outflow, while iDose TR delivers glaucoma medication inside the eye over an extended period. Its iLink platform combines pharmaceutical therapies with ultraviolet light to strengthen and reshape the cornea. The company also develops transdermal treatments for anterior-segment disorders and sustained-release implants for retinal disease. Glaukos operates as one reportable segment and presents its business across five technology platforms. Its customers include ambulatory surgery centers, hospitals, and physician practices, with sales directed to ophthalmic surgeons and other eye-care professionals. In 2025, the iStent family, iDose TR, and related glaucoma accessories represented about 83% of net sales, while iLink products represented about 17%; U.S. customers accounted for 74% of sales. Its website is www.glaukos.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- ALISO VIEJO, CA
- Fiscal year end
- December
- CIK
- 1192448
- SIC
- 3841
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns GLAUKOS Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in GLAUKOS Corp · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · GLAUKOS Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do GLAUKOS Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of GLAUKOS Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in GLAUKOS Corp's last four quarterly filings that the numbers alone won't show?”